Madrigal Pharmaceuticals Inc (MDGL)

322.66 +1.85 (+0.58%) USD  |  NASDAQ  |  Jan 07, 16:00
323.62 +0.96 (+0.30%) After-Hours: 16:14
More

Madrigal Pharmaceuticals Research and Development Expense (Annual): 272.35M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for MDGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Corcept Therapeutics Inc 184.35M
89bio Inc 122.23M
ADMA Biologics Inc 3.30M
Matinas BioPharma Holdings Inc 14.49M
Viking Therapeutics Inc 63.81M